methyl 2-hydroxy-4-(2-methoxyphenyl)-4-oxobut-2-enoate, 97%, 5g

(2S,4R)-1-((S)-14-amino-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamidehydrochloride, 95%, 100mg

Xphos, min 97 %, 10 g, emballage en verre

(R)-2-Amino-but-3-en-1-ol hydrochloride, 97.0%, 1g

Trimethyl(vinyloxy)silane>95.0%(GC)1g

2-(Methoxymethyl)morpholine hydrochloride, 95.0%, 1g

5-Bromo-2-methylbenzyl alcohol, 95%, 25g

1,1,3,3,5,5,7,7,9,9,11,11-Dodecamethylhexasiloxane, 96% GC, 250mg

(S)-tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate hydrochloride, 95%, 100mg

N-(5-Bromo[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide, 97%, 5g

22-Hydroxydocosanoic acid, 98%, 1g

Dibenzoyl D-tartaric acid monohydrate, 99.0%, 1g

3-(4-METHOXYPHENOXY)PROPANENITRILE, 95.0%, 500mg